Anti-Malaria Drug Policy - Ghana Health Service

More documents

Recommendations

Info

ANTI-MALARIA DRUG POLICY FOR GHANA option other than what was first used shall be given where treatment failure is established. 3.0 COMPLICATED (SEVERE) MALARIA Complicated/Severe Malaria is caused by Plasmodium falciparum and confirmed by the presence of the asexual parasite forms in the blood. Management of severe/complicated malaria requires parenteral treatment to provide adequate blood-serum concentrations as quickly as possible initially; subsequently revert to oral treatment as soon as the patient's condition permits. 3.1 Pre-referral treatment of malaria in Homes and Communities All children who do not respond to treatment with Artesunate-Amodiaquine within 24 hours shall be referred immediately to the nearest health facility after tepid sponging. Such children shall be given an initial dose of an artemisinin-based suppository prior to referral to the nearest health facility. MINISTRY OF HEALTH 10
ANTI-MALARIA DRUG POLICY FOR GHANA 3.2 Management of Complicated (Severe) Malaria Quinine or I.M. Artemether shall be the drugs of choice for treating complicated malaria. The necessary support therapy shall be provided as and when appropriate. 3.3 Management of Complicated (Severe) Malaria in Pregnancy 3.3.1 All Trimesters The treatment of pregnant women with severe malaria shall be with parenteral Quinine (I.V. or I.M. in all trimesters) until the patient can take oral preparations 3.3.2 Second and Third Trimesters Intramuscular Artemether injection is recommended for the second and third trimesters. Pregnant women with co-morbidities of HIV and sickle cell anaemia shall be treated as above. MINISTRY OF HEALTH 11
Page 1 and 2: ANTI-MALARIA DRUG POLICY FOR GHANA
Page 7 and 8: ACKNOWLEDGEMENT ANTI-MALARIA DRUG P
Page 19: ANTI-MALARIA DRUG POLICY FOR GHANA
Page 35: successful change particularly in v

Anti-Malaria Drug Policy - Ghana Health Service

Create successful ePaper yourself

Delete template?

Save as template?